|
Critical time Intervention for Severely mentally ill Prisoners (CrISP): a randomised controlled trial |
Shaw J, Conover S, Herman D, Jarrett M, Leese M, McCrone P, Murphy C, Senior J, Susser E, Thornicroft G, Wright N, Edge D, Emsley R, Lennox C, Williams A, Cust H, Hopkin G & Stevenson C |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shaw J, Conover S, Herman D, Jarrett M, Leese M, McCrone P, Murphy C, Senior J, Susser E, Thornicroft G, Wright N, Edge D, Emsley R, Lennox C, Williams A, Cust H, Hopkin G & Stevenson C. Critical time Intervention for Severely mentally ill Prisoners (CrISP): a randomised controlled trial. Health Services and Delivery Research 2017; 5(8) Authors' objectives The transition from prison to community is difficult for prisoners with mental illness. Critical time intervention (CTI) is designed to provide intensive support to meet health, social care and resettlement needs through close working between client and key worker pre, and up to 6 weeks post, release.
The objective was to establish whether or not CTI is effective in (1) improving engagement of discharged male prisoners who have mental illness with community mental health teams (CMHTs) and (2) providing practical support with housing, finance and re-establishing social networks. Authors' conclusions The intervention significantly improved contact with services at 6 weeks, although at a higher cost than the control. This is important as, in the days and weeks following release, recently released individuals are at a particularly high risk of suicide and drug overdose. Further research is required to establish how teams can better maintain contact with clients when the intervention ends. Indexing Status Subject indexing assigned by CRD MeSH Humans; Mental Disorders; Mentally Ill Persons; Prisoners Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence HS&DR Programme, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, University of Southampton, Alpha House, Enterprise Road, Southampton, SO16 7NS, UK Tel: +44 23 8059 4304
Email: hsdrinfo@southampton.ac.uk AccessionNumber 32017000147 Date abstract record published 24/02/2017 |
|
|
|